TORONTO, Nov. 15, 2024 /PRNewswire/ -- A new study published in the Journal of Medical Internet Research by JMIR Publications reveals promising results from a digital health intervention that is based on a decade of research at Harvard Medical School and designed to alleviate depressive symptoms. The study, titled "Facilitating Thought Progression to Reduce Depressive Symptoms: Randomized Controlled Trial," found that participants experienced substantial reduction of depressive symptoms by using

TORONTO, Nov. 15, 2024 /PRNewswire/ -- In a bid to expand the global footprint of its pioneering health and wellness applications, Canadian born business, Myant Corp., a leader in advanced materials for healthcare, today announced the acquisition of Nanoleq and Osmotex, two leading textile computing companies based in Switzerland. Zurich has now been set up as a base for Myant's EU and EMEA expansion. These acquisitions add valuable talent to the company and enhance Myant's lead in textile techn

Organogenesis Pleased to Lead Collaborative Effort to Support Data-Driven Policy on Local Coverage DeterminationCANTON, Mass., Nov. 15, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, commends today’s decision by the U.S. Centers for Medicare & Medicaid Services (CMS) on local cove

ANN ARBOR, Mich.--( BUSINESS WIRE )-- ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS ® ), today reported financial results for the three and nine months ended September 30, 2024 and provided a business update. Highlights from the third quarter and recent weeks include: Developed data analysis features for TAEUS platform by introducing new models rooted in artificial intelligence (AI), machine learning (ML) and deep learning (DL). As part of its c

BECCLES, England--( BUSINESS WIRE )--Automation solutions provider, PCE Automation Ltd completes its second acquisition in just two years, with north Lincolnshire-based vision inspection and web conversion provider, Olmec-UK being the latest addition to its expanding portfolio. The acquisition was a strategic choice, allowing PCE Automation to strengthen its existing presence within the Life Science sector by bringing vision inspection and web conversion capabilities into its offering. PCE plans

Illumina has moved to dismiss a securities lawsuit against the company and former board members over the $8 billion Grail deal, after claiming to refute allegations around a secret financial stake that motivated the transaction. In June, German investors filed litigation that accused former Illumina board members of overpaying for Grail, in part because the directors and others secretly owned $800 million in stock. But in a filing on Tuesday, Illumina said its lawyers showed the plaintiffs’ coun

President-elect Donald Trump has just set up a showdown for the future of biopharma policy during his administration. On one side is Trump’s pick to lead the Department of Health and Human Services, Robert F. Kennedy Jr. Kennedy is an anti-vaccine advocate who, at various points, has called for limiting drug ads, ending some government research on pharma treatments, and a re-review of data supporting vaccine safety. He has called the relationship between the FDA and industry corrupt, and has

SAN DIEGO, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, today announced that company management will participate in three upcoming investment bank conferences. The Piper Sandler 36th Annual Healthcare Conference is being held in New York, NY, and both the Citi Global Healthcare Confere

PALO ALTO, Calif. , Nov. 15, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced presentation of data at the 2024 American College of Rheumatology Convergence conference to be held at the Walter E. Washington Convention Center in Washington, D.C. on November 14 – 19, 2024

MARLBOROUGH, Mass., Nov. 15, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Axonics, Inc. (Nasdaq: AXNX), a medical technology company focused on the development and commercialization of differentiated devices to treat urinary and bowel dysfunction. "Over the last decade, it has been impressive to see the meaningful innovations Axonics has delivered for patients with overactive bladder and incontinence," said Meghan Scanlon, senior